vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $196.0M, roughly 1.0× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 8.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AXSM vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $196.9M |
| Net Profit | $-28.6M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | -13.8% | 1.2% |
| Net Margin | -14.6% | — |
| Revenue YoY | 65.0% | 5.1% |
| Net Profit YoY | 61.9% | — |
| EPS (diluted) | $-0.55 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $196.9M | ||
| Q3 25 | $171.0M | $179.5M | ||
| Q2 25 | $150.0M | $181.1M | ||
| Q1 25 | $121.5M | $168.9M | ||
| Q4 24 | $118.8M | $187.3M | ||
| Q3 24 | $104.8M | $168.6M | ||
| Q2 24 | $87.2M | $178.0M | ||
| Q1 24 | $75.0M | $167.1M |
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $5.4M | ||
| Q2 25 | $-48.0M | $-4.8M | ||
| Q1 25 | $-59.4M | $4.8M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-143.5M | ||
| Q2 24 | $-79.3M | $18.9M | ||
| Q1 24 | $-68.4M | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | -13.8% | 1.2% | ||
| Q3 25 | -27.0% | 3.5% | ||
| Q2 25 | -24.5% | 4.7% | ||
| Q1 25 | -46.9% | 1.2% | ||
| Q4 24 | -61.1% | 13.2% | ||
| Q3 24 | -59.8% | -82.8% | ||
| Q2 24 | -89.5% | 15.9% | ||
| Q1 24 | -89.7% | 7.9% |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 3.0% | ||
| Q2 25 | -32.0% | -2.7% | ||
| Q1 25 | -48.9% | 2.8% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | -85.1% | ||
| Q2 24 | -91.0% | 10.6% | ||
| Q1 24 | -91.1% | 5.4% |
| Q4 25 | $-0.55 | $0.05 | ||
| Q3 25 | $-0.94 | $0.12 | ||
| Q2 25 | $-0.97 | $-0.11 | ||
| Q1 25 | $-1.22 | $0.10 | ||
| Q4 24 | $-1.54 | $0.38 | ||
| Q3 24 | $-1.34 | $-3.11 | ||
| Q2 24 | $-1.67 | $0.39 | ||
| Q1 24 | $-1.44 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $88.3M | $693.1M |
| Total Assets | $689.8M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $238.4M | ||
| Q3 25 | $325.3M | $246.3M | ||
| Q2 25 | $303.0M | $445.9M | ||
| Q1 25 | $300.9M | $493.6M | ||
| Q4 24 | $315.4M | $484.6M | ||
| Q3 24 | $327.3M | $453.8M | ||
| Q2 24 | $315.7M | $404.2M | ||
| Q1 24 | $331.4M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $88.3M | $693.1M | ||
| Q3 25 | $73.7M | $727.2M | ||
| Q2 25 | $73.1M | $757.8M | ||
| Q1 25 | $53.2M | $798.5M | ||
| Q4 24 | $57.0M | $778.3M | ||
| Q3 24 | $92.9M | $749.6M | ||
| Q2 24 | $102.9M | $879.3M | ||
| Q1 24 | $144.0M | $892.2M |
| Q4 25 | $689.8M | $1.3B | ||
| Q3 25 | $669.3M | $1.3B | ||
| Q2 25 | $639.8M | $1.5B | ||
| Q1 25 | $596.7M | $1.6B | ||
| Q4 24 | $568.5M | $1.6B | ||
| Q3 24 | $561.5M | $1.5B | ||
| Q2 24 | $548.2M | $1.6B | ||
| Q1 24 | $545.7M | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $43.7M |
| Free Cash FlowOCF − Capex | $-18.7M | $43.5M |
| FCF MarginFCF / Revenue | -9.6% | 22.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $43.7M | ||
| Q3 25 | $1.0M | $60.8M | ||
| Q2 25 | $-32.4M | $12.0M | ||
| Q1 25 | $-43.4M | $35.5M | ||
| Q4 24 | $-26.2M | $33.1M | ||
| Q3 24 | $-18.6M | $53.9M | ||
| Q2 24 | $-30.1M | $53.2M | ||
| Q1 24 | $-53.5M | $49.1M |
| Q4 25 | $-18.7M | $43.5M | ||
| Q3 25 | $988.0K | $57.0M | ||
| Q2 25 | $-32.4M | $9.3M | ||
| Q1 25 | $-43.7M | $26.9M | ||
| Q4 24 | $-26.2M | $31.0M | ||
| Q3 24 | $-18.7M | $49.8M | ||
| Q2 24 | $-30.2M | $51.6M | ||
| Q1 24 | $-53.6M | $46.3M |
| Q4 25 | -9.6% | 22.1% | ||
| Q3 25 | 0.6% | 31.7% | ||
| Q2 25 | -21.6% | 5.1% | ||
| Q1 25 | -36.0% | 15.9% | ||
| Q4 24 | -22.1% | 16.6% | ||
| Q3 24 | -17.9% | 29.6% | ||
| Q2 24 | -34.6% | 29.0% | ||
| Q1 24 | -71.4% | 27.7% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.3% | 5.1% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.1% | 0.9% | ||
| Q1 24 | 0.1% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
